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Abstract
A major obstacle in human stem cell research is the limited number of reagents capable of distinguishing pluripotent stem
cells from partially differentiated or incompletely reprogrammed derivatives. Although human embryonic stem cells (hESCs)
and induced pluripotent stem cells (iPSCs) express numerous alternatively spliced transcripts, little attention has been
directed at developing splice variant-encoded protein isoforms as reagents for stem cell research. In this study, several
genes encoding proteins involved in important signaling pathways were screened to detect alternatively spliced transcripts
that exhibited differential expression in pluripotent stem cells (PSCs) relative to spontaneously differentiated cells (SDCs).
Transcripts containing the alternatively spliced exon 10 of the de novo DNA methyltransferase gene, DNMT3B, were
identified that are expressed in PSCs. To demonstrate the utility and superiority of splice variant specific reagents for stem
cell research, a peptide encoded by DNMT3B exon 10 was used to generate an antibody, SG1. The SG1 antibody detects a
single DNMT3B protein isoform that is expressed only in PSCs but not in SDCs. The SG1 antibody is also demonstrably
superior to other antibodies at distinguishing PSCs from SDCs in mixed cultures containing both pluripotent stem cells and
partially differentiated derivatives. The tightly controlled down regulation of DNMT3B exon 10 containing transcripts (and
exon 10 encoded peptide) upon spontaneous differentiation of PSCs suggests that this DNMT3B splice isoform is
characteristic of the pluripotent state. Alternatively spliced exons, and the proteins they encode, represent a vast untapped
reservoir of novel biomarkers that can be used to develop superior reagents for stem cell research and to gain further
insight into mechanisms controlling stem cell pluripotency.
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Introduction
Advancements in the studies of human embryonic stem cells
(hESCs) and induced pluripotent stem cells (iPSCs) have created
new opportunities for basic research and regenerative medicine
[1]. These cells have wide-ranging applications in cell replacement
therapies, development of model systems for studying diseases and
drug testing. To realize the full potential of pluripotent stem cells
(PSCs), however, many hurdles must be overcome. For example,
PSCs propagated in vitro often spontaneously differentiate into
unknown or undesired cells types. Although spontaneous differ-
entiation of mouse ES cells can be prevented by supplementing the
media with leukemia inhibitory factor (LIF), LIF does not prevent
differentiation of human ES cells and comparable factors have not
been identified [2]. In addition, limitations in the ability to detect
dynamic changes in PSCs during self-renewal and early stages of
differentiation are due primarily to a dearth of reliably accurate
and sensitive detection assays. Additional reagents are needed to
detect loss of pluripotency and to refine culture conditions that
promote maintenance of the pluripotent state.
The transcriptional profiles of hESC and iPSC genes that
regulate self-renewal, asymmetric cell division and signaling
pathways are currently being characterized; however, relatively
little is known about post-transcriptional gene regulatory mecha-
nisms that operate in PSCs. Bioinformatic analysis of expressed
sequence tags deposited in public databases indicate that hESCs
express alternatively spliced variants of many genes that play
important roles in signaling pathways that have been implicated in
development and differentiation [3]. Hybridization of RNA
isolated from hESCs and neural progenitors to exon microarrays
identified several genes for which expression ratios of alternative
splice variants differed during neural differentiation [4]. The
widespread alternative splicing observed across various classes of
hESC genes, including multiple components of signaling path-
ways, strongly suggests that alternative splicing is a key regulator of
hESC gene expression. Despite these findings, little effort has been
directed at investigating alternatively spliced variants as unique
markers of pluripotency, specific differentiation stages or cell type
lineages.
In this study, we demonstrate that several signaling pathway
genes exhibit changes in alternative splicing patterns during the
transition from PSCs to spontaneously differentiated cells (SDCs).
Specific exons that were expressed at high levels in PSCs, but not
expressed (or expressed at lower levels) in SDCs were identified. As
proof-of-principle, one pluripotent stem cell-specific, alternatively
spliced exon was used to generate a peptide-specific polyclonal
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ing human PSCs from cells undergoing early stages of spontaneous
differentiation.
Materials and Methods
Pluripotent stem and differentiated cell culture
Karyotypically normal PSCs, including three hESC lines (H9
[WiCell], HES4 [IS], BG01 [Bresagen]) and the iPSC foreskin
clone 1 (a generous gift from Dr. James Thomson, [5]), were
maintained either on gamma-irradiated mouse embryonic fibro-
blasts feeder layer (CF-1, ATCC) or under feeder-independent
conditions on matrigel coated dishes (BD) as described in detail
previously [6] and briefly below. The hESCs were expanded on
matrigel prior to harvesting RNA and protein to prevent any
contamination from MEF-derived mouse gene products in
molecular experiments. Media contained DMEM/F-12 with
glutamine, 20% knockout serum replacement, 2 mM non-essential
amino acids (all from Invitrogen) and 20 ng/ml zbFGF [7]. Cells
were cultured under 5% CO2 at 37uC. For passaging, 5–6 day old
hESC colonies were cut into small pieces (100–200 cells) by
mechanical dissection using a 27G hypodermic needle and
transferred to new dishes at a split ratio of 1:3. To obtain
spontaneously differentiated cells, undifferentiated PSC colonies
grown on matrigel were fed with hESC media without zbFGF for
the number of days indicated in each figure legend. Specifically,
mixed cultures of PSCs and SDCs were produced by culturing in
the absence of zbFGF for 4–5 days, while relatively homogeneous
cultures of SDCs were obtained by maintaining in culture minus
zbFGF for 14–15 days. Cultures of homogeneous SDCs (14–15
Figure 1. Human PSCs exhibit differential expression of alternative splice variants as the cells spontaneously differentiate. RT-PCR
analysis using exon-specific primers was performed using total RNA isolated from pluripotent stem cells (PSCs) or cells that had undergone
spontaneous differentiation for 14–15 days (SDCs). Gene names are on the left and PCR product size (MW) and exon identity (exon) are indicated on
the right. 18sRNA was used as control in RT-PCR reactions.
doi:10.1371/journal.pone.0020663.g001
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entiated cells, which were removed from the dish prior to
harvesting RNA or protein for molecular experiments.
Semi-quantitative and realtime RT-PCR analysis
Total RNA was isolated from pluripotent stem and differentiated
cells using the TRIzol method according to the manufacturer’s
(Invitrogen) instructions. To examine splice variant expression,
cDNAs were synthesized from total RNA (2 mg) using the
SuperScript II reverse transcriptase kit (Invitrogen) and random
primers. PCR reactions were carried out using cDNA (1 ml) and
exon-specific primers (Table S1) designed from information
contained in alternative splicing databases such as Fast-DB
(http://193.48.40.18/fastdb/), Ensembl (www.ensembl.org/index.
html), Hollywood (http://hollywood.mit.edu/hollywood/) and
UCSC genome browser (http://genome.ucsc.edu/). PCR products
were resolved by electrophoresis on 1.5% agarose gels and
visualized by ethidium bromide staining. Data were recorded using
QuantityOne software (Biorad). PCR products of interest were
excised, purified and directly sequenced or subcloned into pSC-A
(Stratagene) and sequenced (Figure S1). Realtime RT-PCR was
performed in duplicate for each sample in an iCycler (BioRad).
Reactions (25 ml) contained cDNA template (1 ml), exon-specific
primers and SYBR green PCR mix (Applied Biosystems). Relative
quantification was done by the DDCT method [8].
Peptide antibody development
Open Biosystem (Huntsville, AL) synthesized the peptide,
KSKVRRAGSRKLESR, encoded by DNMT3B exon 10, and
produced the polyclonal antibodies. Two rabbits were injected
with the above peptide conjugated to keyhole limpet hemocyanin.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Use Committee
(IACUC) of Thermo Scientific, Open Biosystems (NIH (OLAW)
assurance number: A3669-01; expires 03/31/2012; USDA
(research license) registration number: 23-R-0089; expires 06/
06/2011; PHS assurance number: A3669-01; expires 03/31/
2012). Peptide antibody specificity was determined by ELISA and
the affinity purified a-DNMT3B exon 10-encoded peptide-specific
rabbit polyclonal antibody was designated SG1.
Immunofluorescence staining of PSCs and SDCs
Cells were grown on matrigel-coated LabTek four or eight
chamber slides, rinsed briefly with 16 PBS and fixed with 4%
paraformaldehyde for 30 min at room temperature (RT). Samples
were blocked with a solution containing 5% donkey serum and 5%
Triton 6100 in 16PBS for one hour at RT, then incubated with
primary antibodies at 4uC overnight. Primary antibodies used
included rabbit polyclonal a-OCT4 (1:100, Cell Signaling, catalog
# 2750), goat polyclonal a-OCT4 (1:100, Santa Cruz, catalog #
SC-8628), mouse monoclonal a-OCT4 (POU5F1; 1:100, Sigma
catalog # P0082), mouse monoclonal a-TRA-1-60 (1:500, Cell
Signaling, catalog # 4746), rabbit polyclonal a-DNMT3B (H-230,
1:100, Santa Cruz, catalog # 20704), rabbit polyclonal
a-DNMT3B (CS, 1:100, Cell Signaling, catalog # 2161) and
rabbit polyclonal SG1 (1:100). After overnight incubation with
primary antibody, slides were washed four times with 16 PBS,
incubated with secondary antibodies for one hour at RT and
washed four times with 16PBS. Secondary antibodies, purchased
from R&D system, included a-mouse IgG-NL493 (catalog #
NL009), a-rabbit IgG-NL493 (catalog # NL006), a-goat IgG-
NL493 (catalog # NL003), a-rabbit IgG-NL557 (catalog #
NL004) and a-mouse IgG-NL557 (catalog # NL007). Secondary
antibodies, purchased from Invitrogen, included a-mouse IgG-
Alexa fluor 488 (catalog # 11017), a-mouse IgM-Alexa fluor 488
(catalog # A21042) and a-rabbbit IgG Alexa fluor 545 (catalog #
A11071). All secondary antibodies were used at 1:500 dilutions.
Cells were counter-stained using Hoechst/16PBS and coverslips
mounted using Vectashield mounting medium. Fluorescence
images were captured on an Olympus Inverted IX81 fluorescence
microscope. All images of cells are shown at 1006magnification
except as indicated in the figure legends.
Western blots
Pluripotent and spontaneously differentiated cells were grown
on six well matrigel-coated plates under feeder-independent
conditions. Cells were rinsed twice with ice cold PBS and 0.5 to
1 ml of RIPA lysis buffer (Sigma) was added. Plates were kept at
4uC for 5 min. Lysate was clarified by centrifugation (10,000 g,
Figure 2. Exon 10-included DNMT3B splice variant is expressed
at higher levels in pluripotent stem cells. A. Depiction of
alternative splicing of DNMT3B exon 10 and location of PCR primers
for qRT-PCR reactions. B. Quantitative changes in expression of DNMT3B
exon 10, as measured by realtime PCR, in undifferentiated pluripotent
stem cells (PSCs) or spontaneously differentiated cells (SDCs; 14–15
days), in the H9 hESC, BG01 hESC and foreskin-1 iPSC lines.
doi:10.1371/journal.pone.0020663.g002
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were quantified using the BCA method (Pierce). Protein (15 mg/
lane) was separated by electrophoresis on a 5–15% SDS
polyacrylamide gel and blotted to a nitrocellulose filter using a
semi-dry blotter apparatus (Bio-Rad). Primary antibodies used for
Western blots were SG1 (1:100), rabbit polyclonal a-OCT4
(1:100) and mouse monoclonal a-GAPDH (1:200, Santa Cruz,
catalog # SC-47724). Secondary antibodies were horseradish
peroxidase-coupled a-rabbit IgG (1:10000; Santa Cruz) or a-
mouse IgG (1:10000; Santa Cruz). Secondary antibodies were
detected using the ECL plus Western blotting detection system
(GE Healthcare). For the dot blot assay, DNMT3B exon 10
peptide antigen was adsorbed to PVDF membrane (BioRad
#162-0174) at decreasing concentrations, incubated with SG1
antibody (1:100) or pre-immune sera (1:100) followed by
incubation with secondary antibody (horseradish peroxidase
coupled a-rabbit IgG, 1:10000, Santa Cruz), and the blot
developed using the ECL plus Western blotting detection system.
Results
Alternative splice variants of signaling pathway genes are
differentially expressed as pluripotent stem cells
spontaneously differentiate
To identify splice variants that displayed unique expression
patterns in PSCs relative to SDCs, three hESC lines (H9, HES4,
BG01) and one iPSC line (foreskin-1) were cultured under
conditions that either maintained the pluripotent state or induced
Figure 3. DNMT3B exon 10 and encoded peptide sequence used for immunization. A. Sequence of DNMT3B exon 10 encoding a 15 amino
acid peptide used for generating the SG1 peptide antibody. B. Dot blot analysis demonstrating specificity of SG1 antibody relative to pre-immune
sera. Decreasing quantities (in mg) of peptide antigen were adsorbed to the membrane, incubated with either the SG1 antibody or pre-immune sera,
incubated with secondary antibody and the blot developed as described in Materials and Methods. Pre-immune sera detects no peptide antigen
even at the highest concentration.
doi:10.1371/journal.pone.0020663.g003
Figure 4. DNMT3B exon 10 encoded peptide antibody, SG1, detects pluripotent stem cells. Dual immunofluorescence assay of
undifferentiated pluripotent stem cell lines, H9, HES4 and iPSC stained with OCT4 or SG1 antibodies. Phase contrast image of stem cell colonies
(Phase) and same colony stained with Hoechst dye (Hoechst; blue), OCT4 antibody (OCT4; green), and SG1 antibody (SG1; red).
doi:10.1371/journal.pone.0020663.g004
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included those with known or predicted splice variants that had
been deposited in several alternative splicing databases (Materials
and Methods) or alternatively spliced genes that had been
implicated in stem cell differentiation in other organisms [3]. An
emphasis was placed on genes encoding signaling proteins
because of the probability that these genes are not simply
markers of ‘stemness’ but play a functional role in maintaining
the pluripotent state and, thus, may exhibit tighter regulation of
splice variant expression as a function of pluripotency. Total
RNA was extracted from PSCs and corresponding SDCs and
subjected to semi-quantitative RT-PCR analysis using exon-
specific primers. This analysis confirmed the existence of
numerous alternatively spliced variants and revealed interesting
changes in splicing patterns and expression ratios of splice
isoforms as cells transitioned from the pluripotent to the
spontaneously differentiated state (Figure 1).
The differential splicing patterns observed in PSCs relative to
SDCs fell into four general categories. In the most prevalent
category, the exon-excluded splice variant was expressed at higher
levels in SDCs relative to PSCs. These genes included STAT3
(signal transducer and activator of transcription 3), SAM68 (KH domain
containing, RNA binding, signal transduction associated 1), KLF6 (Kruppel-
like factor 6), SHC1 (SHC transforming protein 1) and TBC1D3P2
(TBC1 domain family member 3, pseudogene 2) (Figure 1). The second
general category included those genes for which the exon-excluded
variant was expressed at higher levels in PSCs than SDCs.
Examples included FES (feline sarcoma oncogene), CDC25A (cell division
cycle 25 homolog A) and TYK2 (tyrosine kinase 2). In addition to precise
exon skipping, some genes selected for comparison (e.g. FES),
exhibited complex changes in alternative splicing pattern including
generation of a novel splice isoform that arises by utilization of a 39
acceptor site located within the downstream exon.
For many of the splice variants, the length of the excluded exon
was a multiple of three, indicating that precise exon skipping
preserved the open reading frame and suggesting that the excluded
exons encode important protein structural, functional or regula-
tory domains. For the exon-excluded splice variants, one could
design a peptide encoded by sequences spanning the exon junction
and use this ‘exon junction’ peptide to raise antibodies that might
distinguish between proteins translated from exon-excluded vs.
exon-included transcripts; however, this approach is less straight-
forward than generating antibodies to peptides encoded by
differentially included exons. Therefore, we were primarily
interested in identifying splice variants in which the exon-included
variant was expressed at higher levels in either PSCs or SDCs.
These splice variants were found in the two remaining general
categories: those genes for which the exon-included variant was
expressed at higher levels in SDCs than PSCs or those for which
the exon-included variant was expressed at higher levels in PSCs
relative to SDCs. Among the genes analyzed, the third category
was least common. In general, exon-included variants were
expressed at similar or higher levels in PSCs than SDCs, indicating
that the frequency of exon skipping increases after differentiation
or is concomitant with loss of pluripotency. Nonetheless, for
NUBP2 (nucleotide binding protein 2) the exon-included variant was
expressed at higher levels in SDCs than PSCs (Figure 1). However,
it is unlikely that a NUBP2 exon 3 peptide-specific antibody would
be a reliable marker of SDCs, since overall expression of NUBP2
was low and its exon 3-included splice variant was also expressed
in PSCs.
In the final category, the exon-included variant was expressed at
higher levels in PSCs than SDCs. These genes included NDKA
(Nucleoside diphosphate kinase A), P2RX5 (purinergic receptor P2X, ligand-
gated ion channel 5) and DNMT3B (DNA cytosine-5-methyltransferase 3
beta). In the case of NDKA, the exon 2-included variant was
expressed at low levels in PSCs and disappears during spontaneous
differentiation. Both the exon 3-included and exon 3-excluded
variants of P2RX5 were expressed at higher levels in PSCs
compared to SDCs. In addition, an unknown P2RX5 splice variant
that migrated above the full-length product was specifically
expressed in SDCs (Figure 1). Although these splice variants
might be suitable for antibody production, the low level expression
of the NDKA exon 2-included splice variant in PSCs and the fact
that the P2RX5 exon 3-included splice variant persisted in SDCs
indicates that they are not ideal candidates for antibody
production since protein expression levels may be too low to be
detectable and/or expression is not unique to PSCs or SDCs.
However, RT-PCR analysis of DNMT3B splice variants in PSCs
relative to SDCs indicated that DNMT3B encodes at least one
ideal candidate for antibody production. Two primer pairs were
Figure 5. DNMT3B protein containing the exon 10-encoded
peptide is expressed only in pluripotent stem cells. Western blot
analysis using DNMT3B exon 10 peptide antibody (SG1), OCT4 and
GAPDH (control) antibodies to detect proteins expressed in pluripotent
stem (PSCs) and spontaneously differentiated cells (SDCs; 14–15 days).
doi:10.1371/journal.pone.0020663.g005
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one pair, an exon 20 forward primer was used in conjunction with
an exon 23 reverse primer to examine differential expression of the
DNMT3B catalytic domain encoded by exons 21 and 22. The full-
length isoform was predominately expressed in PSCs, and its
expression decreased, but did not disappear, during the transition
from PSCs to SDCs. DNMT3B transcripts lacking exons 21 and 22
were also detected in PSCs and their expression level increased
upon differentiation (Figure 1). In contrast, the primer pair specific
for exons 9 (forward) and 11 (reverse) amplified a major DNMT3B
transcript containing exon 10 that was specifically expressed in
PSCs and absent from SDCs. A similar finding was reported for
mouse ES cells where undifferentiated cells express DNMT3B
transcripts that include exon 10, while exon 10 is excluded from
DNMT3B transcripts in differentiated cells [9]. To confirm that
DNMT3B exon 10 was uniquely expressed in PSCs, realtime RT-
PCR analysis was performed with an exon 9 forward primer and
an exon 10 reverse primer (Figure 2A) using RNA extracted from
three pluripotent stem cell lines (H9, BG01 and iPSC) and their
respective spontaneously differentiated derivates. DNMT3B exon
10 expression levels were 11-fold higher in H9 PSCs vs. H9 SDCs,
13-fold higher in BG01 PSCs vs. BG01 SDCs and 32-fold higher
in iPSCs vs. iPSC SDCs (Figure 2B).
Peptides encoded by alternatively spliced exons can be
used to raise antibodies that distinguish pluripotent
stem cells from early stage differentiated cells
Given the abundant, restricted expression of DNMT3B exon 10-
included transcripts in PSCs relative to SDCs, this sequence was
Figure 6. SG1 antibody identifies pluripotent stem cells in mixed populations. Mixed populations of pluripotent and early-stage
spontaneously differentiated cells (4–5 days minus zbFGF) obtained from (A) BG01 hESC line or (B) foreskin-1 iPSC line were stained with SG1 antibody
and compared to cells stained with a-OCT4 polyclonal and two commercially available a-DNMT3B polyclonal antibodies, one from Cell Signaling (CS)
and one from Santa Cruz (H-230). Phase contrast image of stem cell colonies (Phase) and same cells stained with Hoechst dye (Hoecsht; blue), a-OCT4
antibody (OCT4; green) and one of three different a-DNMT3B antibodies (DNMT3B; red) as indicated on the right. The a-DNMT3B antibodies used
included the custom peptide antibody, SG1 (top), or one of two commercial antibodies, CS (middle) or H-230 (bottom). Compact colonies of pluripotent
stem cells are indicated by large arrows, while dispersed spontaneously differentiated cells are indicated by small arrows in the phase contrast images.
doi:10.1371/journal.pone.0020663.g006
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sequence was designed on the basis of the human DNMT3B exon
10 genomic sequence (Figure 3A). Sequence alignment using
BLAST confirmed this sequence was specific to DNMT3B exon 10
and BLASTP confirmed the peptide sequence was unique. The 15
amino acid peptide was synthesized and used as antigen for
immunization of rabbits. Specificity of the SG1 antibody relative
to pre-immune sera was confirmed by performing dot blot analysis
against decreasing concentrations of the peptide antigen used for
immunization (Figure 3B).
The affinity purified a-DNMT3B exon 10 encoded peptide
polyclonal antibody, SG1, was first tested for its ability to detect
DNMT3B expression in PSCs. Three undifferentiated pluripotent
stem cell lines (H9, HES4 and iPSC) were cultured for 5–6 days
and immunofluorescence staining was performed using a dual
staining procedure to identify cells that stained positive with
OCT4 and/or SG1 antibodies. OCT4 was chosen for comparison
because it is considered a definitive marker of pluripotency.
Complete overlap of OCT4 and SG1 staining was observed in
both hESCs and iPSCs (Figure 4), indicting that the SG1 antibody
identifies pluripotent stem cells.
We then asked if the SG1 antibody detects DNMT3B protein
on Western blots of proteins extracted from four PSC lines (H9,
HES4, BG01 and iPSC) and their corresponding spontaneously
differentiated derivatives (14–15 days minus zbFGF). The SG1
antibody detected high-level expression of a single band of the
expected MW (,100 kD) that was present in all four PSC lines,
but did not detect any protein in any of the four SDC populations
(Figure 5). In contrast, low-level expression of OCT4 protein was
detected in SDCs of all three hESC lines examined. Interestingly,
OCT4 expression remained fairly high in SDCs derived from the
iPSC line, suggesting that the OCT4 transgene used to create this
iPSC line may still be expressed even after differentiation.
To confirm the utility of the SG1 antibody at distinguishing PSCs
from SDCs in mixed populations containing both pluripotent stem
cells and spontaneously differentiated derivatives, two pluripotent
stem cell lines (BG01 and iPSC) were examined for SG1 staining
while the cells were undergoing early stages of spontaneous
differentiation. Undifferentiated PSC colonies were grown for four
to five days in stem cell media in the absence of zbFGF until SDCs
appeared. Immunofluorescence staining of these partially differen-
tiated colonieswasperformedusingthe SG1antibodyincomparison
to the a-OCT4 and two commercially available rabbit polyclonal a-
DNMT3B antibodies. Low-level OCT4 expression was detected in
SDCs derived from the BG01 hESC line. Neither DNMT3B
commercial antibody distinguished PSCs from SDCs (Figure 6A).
Similar results were obtained using mixed populations of PSCs and
SDCs derived from the iPSC line (Figure 6B). In marked contrast,
the custom a-DNMT3B peptide antibody, SG1, was highly specific
to PSCs and did not stain SDCs in mixed populations of either the
BG01 hESC (Figure 6A) or the iPSC (Figure 6B) lines.
These results indicate that the SG1 antibody detects a unique
DNMT3B protein isoform exhibiting an expression profile that is
restricted to pluripotent stem cells. Given that expression of the
DNMT3B protein isoform is down regulated faster than OCT4
protein upon spontaneous differentiation of pluripotent stem cells,
we than asked if transcripts containing DNMT3B exon 10 also
exhibit more tightly restricted expression than OCT4 transcripts in
cells undergoing early stages of spontaneous differentiation. For
this experiment, we compared the time course of down regulation
of DNMT3B exon 10 included transcripts relative to OCT4
transcripts by quantitative RT-PCR analysis. H9 hESCs were
induced to spontaneously differentiate by removal of zbFGF from
the culture media. Cells were harvested at days 0, 3, 6, 9, 12 and
15, RNA extracted and qRT-PCR analysis performed using
primer pairs specific for DNMT3B exon 10 (as depicted in
Figure 2A and shown in Table S1) or OCT4 (Table S1). Relative
transcript expression levels were plotted as a function of number of
days following induction of differentiation (Figure 7). The time
course experiment demonstrates that DNMT3B exon 10 contain-
ing transcripts also exhibit faster down regulation than OCT4
transcripts upon spontaneous differentiation. By day 6, which
corresponds to early stages of spontaneous differentiation, OCT4
transcripts in SDCs are expressed at levels equivalent to 42% of
that detected in PSCs, while DNMT3B exon 10 transcripts have
been reduced to 32% of the original level in PSCs; by day 15 (late
stage spontaneous differentiation) OCT4 transcripts in SDCs are
still expressed at levels as high as about 13% the original level in
PSCs, while expression levels of DNMT3B exon 10 transcripts
have decreased significantly and are now expressed at levels less
than 0.2% the original level observed in PSCs.
To further confirm the observed faster down regulation of the
DNMT3B exon 10 encoded peptide antigen relative to other
protein biomarkers of pluripotent stem cells, we reexamined
protein expression in mixed cultures of PSCs and SDCs using
monoclonal antibodies detecting stem cell markers OCT4 and
TRA-1-60 and compared their expression to that of the DNMT3B
exon 10 encoded peptide antigen detected by the SG1 rabbit
polyclonal antibody. H9 PSC colonies were grown in stem cell
media in the absence of zbFGF for four to five days until SDCs
appeared. Dual staining for the intracellular markers OCT4 and
DNMT3B in mixed cultures undergoing early stage differentiation
demonstrates that every cell that is detected by the SG1 antibody is
also detected by the OCT4 antibody, indicating that DNMT3B
exon 10 encoded peptide expression is restricted to those cells that
express high-level OCT4 protein (Figure 8A). The converse,
however, is not true. A number of cells, particularly those at a
distance from the main colony, exhibit high-level OCT4
expression but are not stained by the SG1 antibody, indicating
that DNMT3B exon 10 encoded peptide expression is tightly
restricted to PSCs, while OCT4 protein expression persists in
early-stage SDCs. Similar results were obtained when using a dual
Figure 7. Time course of expression of DNMT3B exon 10
containing transcripts relative to OCT4 transcripts in sponta-
neously differentiating cells. RNA extracted from H9 cells induced to
differentiate by removal of zbFGF from the media for the indicated
number of days (0, 3, 6, 9, 12 or 15) was subjected to qRT-PCR analysis.
Relative expression levels of OCT4 transcripts (black bars) in comparison
to DNMT3B exon 10 containing transcripts (white bars) are plotted as a
function of the number of days of spontaneous differentiation. Duplicate
qRT-PCR experiments were performed for each sample; the mean of the
two experiments is plotted with SEM indicated by the error bars.
doi:10.1371/journal.pone.0020663.g007
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peptide expression relative to the cell surface expressed stem cell
marker, TRA-1-60 (Figure 8B). Again, every cell detected by the
SG1 antibody is also detected by the TRA-1-60 monoclonal
antibody, while numerous cells, particularly those at a distance
from the main colony, are stained by the TRA-1-60 antibody but
not by the SG1 antibody, indicating that DNMT3B exon 10
encoded peptide expression is tightly restricted to PSCs, while
TRA-1-60 protein expression persists in early-stage SDCs.
Discussion
Among the many bottlenecks in human PSC research are an
inability to prevent spontaneous differentiation of the cells in culture
and the lackof robust,reliablyspecific reagentsthatdistinguishPSCs
from SDCs. Properties such as the ability to self renew or
differentiate into cells of all three lineages are hallmarks of pluri-
potent stem cells that are controlled by exquisite gene regulatory
mechanismsthatoperate atmultiplelevels, including transcriptional,
post-transcriptional, translational and post-translational. Although
Figure 8. SG1 antibody is superior to OCT4 and TRA-1-60 antibodies at identifying pluripotent stem cells in mixed populations.
Mixed populations of pluripotent and spontaneously differentiated cells (4–5 days minus zbFGF) obtained from the H9 hESC line were analyzed by
dual immunofluorescence staining using SG1 rabbit polyclonal antibody and mouse monoclonal antibodies to OCT4 (A) or TRA-1-60 (B). A. Brightfield
images of stem cell colonies (Brightfield) and same cells stained with Hoechst dye (Hoecsht; blue), a-OCT4 antibody (OCT4; green) and a-DNMT3B
exon 10 encoded peptide (SG1; red) are shown. OCT4 and SG1 staining patterns are overlaid (Merge) and the area outlined by the white box in the
Merge panel is shown in the Magnification panel to facilitate visualization of precise staining patterns in individual cells. The large arrow in the
Magnification panel indicates a cell exhibiting high level expression of both OCT4 and SG1 (in this case, the cell is undergoing mitosis and the SG1
antibody ‘paints’ the chromatids of the dividing cell), the small arrow identifies a cell exhibiting high OCT4 but low SG1 staining, while the large
arrowhead indicates a cell still expressing high levels of OCT4 that is not stained by the SG1 antibody. B. Similar analysis as in A (above) using a
monoclonal antibody that detects the stem cell marker TRA-1-60 (green). As opposed to the intracellular proteins (above), the TRA-1-60 antibody
detects the expected TRA-1-60 expression on the cell surface. While high-level TRA-1-60 expression is detected on almost all cells (both PSCs and
SDCs), SG1 staining is more tightly restricted to PSCs or those cells in very early stages of spontaneous differentiation. All images are shown at 1006
magnification with the exception of the two ‘‘Magnification’’ panels, which were increased in size by about 12 fold in order to allow visualization of
individual cells.
doi:10.1371/journal.pone.0020663.g008
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20663more than 70% of human genes are alternatively spliced and
alternative splicing is a major source of generating proteome
diversity [10], its importance in stem cell research has been
underappreciated and, to some extent, unrecognized. Rather than
relying on differences in whole gene transcription to identify new
markers of pluripotency, our approach relied on identifying
alternatively spliced, protein-coding exons that were abundantly
and uniquely expressed in PSCs. We focused on a few genes
encoding components of signaling pathways that had been
previously implicated in stem cell maintenance and differentiation
because we suspected their alternative splicing patterns would be
tightly regulated between the pluripotent and the spontaneously
differentiated states.
Three hESC lines (H9, HES4 and BG01) and one human iPSC
line (foreskin-1) were included in our study. Differential expression
ofalternativelysplicedexonswasfunctionallyvalidatedbyRT-PCR
and, in some cases, by direct sequencing. One particularly
promising candidate, DNMT3B exon 10, was selected for
generation of a peptide-specific polyclonal antibody, SG1. Restrict-
ed expression of DNMT3B exon 10 and the DNMT3B exon 10-
encoded peptide to PSCs was confirmed by both qRT-PCR and
Western blot analyses. The ability of the SG1 antibody to
distinguish PSCs from SDCs was also compared to several
commercially available polyclonal and monoclonal antibodies
detecting stem cell proteins OCT4 and TRA-1-60. In every case,
the DNMT3B exon 10-encoded peptide exhibited expression that
was more restricted to PSCs. Because OCT4 transcripts and OCT4
protein expression are currently considered the ‘gold standard’ for
identification of pluripotent stem cells [11], our results indicate that
DNMT3B alternatively spliced exon 10 and the SG1 antibody are
superior reagents for distinguishing PSCs from partially differenti-
ated derivates and can be used to better monitor the progressive loss
of ‘stemness’ as hESCs differentiate, or the progressive gain of
‘pluripotency’ during nuclear reprogramming of iPSCs.
DNMT3B is a member of the DNA methyltransferase family
that was identified as a de novo methylation agent of the human
genome. The human DNMT3B gene encodes as many as 40
different isoforms through alternative splicing of DNMT3B
transcripts. Various DNMT3B splice isoforms are highly expressed
in the human female germ line, preimplantation embryos, and
embryonic stem cells, and are differentially expressed during
development and tumorigenesis [12,13,14]. DNMT3B was iden-
tified as a commonly overexpressed marker of 59 hESC lines by
microarray analysis [15]; however, uniquely expressed splice
variants are not generally detectable using conventional cDNA
microarrays. DNMT3B was also suggested to be a specific marker
of bona fide human pluripotent stem cells based on qRT-PCR
analysis that did demonstrate a high degree of specificity of
expression of DNMT3B transcripts in PSCs relative to partially
reprogrammed cells [16]. This result, however, can be explained
by the fortuitous choice of a PCR forward primer containing only
DNMT3B exon 10 sequences. Therefore, it is important to
recognize that not all DNMT3B transcripts or DNMT3B protein
isoforms are unique and reliable markers of pluripotent stem cells.
DNMT3A and DNMT3B are two major de novo DNA
methyltransferases. Loss of one or both results in abnormal global
DNA methylation patterns; however, loss of DNMT3B (unlike
DNMT3A) also results in hypomethylation of centromeric and
pericentromeric satellite regions that leads to centromeric
instability and mitotic defects [17]. Although the precise function
of the DNMT3B exon 10-encoded peptide domain remains
unknown, it lies between the PWWP and the ring-type zinc finger
domains suggesting that it may play a role in modulating protein-
protein interactions important for DNMT3B binding to
H4K20me and/or targeting of DNMT3B to particular chromo-
somal sites [9,18]. A series of recent reports indicate that gene
expression profiles of iPSCs and hESCs are non-identical and that
some iPSCs retain an epigenetic memory of their cell type of origin
that could arise from distinct global and/or gene–specific DNA
methylation patterns [19,20,21,22,23,24,25]. Furthermore, recent
evidence indicates that the Werner Syndrome gene product,
WRNp, localizes to the OCT4 promoter of human PSCs
undergoing retinoic acid induced differentiation where it plays a
role in de novo DNA methylation by recruiting DNMT3B to the
OCT4 promoter [26]. These results raise the intriguing hypothesis
that proteins encoded by DNMT3B exon 10-containing transcripts
may play a crucial role in establishing de novo DNA methylation
patterns that are characteristic of the pluripotent state perhaps by
regulating transcription of the pluripotency transcription factor,
OCT4, and, in so doing, might affect the efficiency and/or
stability of nuclear reprogrammed iPSCs. Finally, the previously
noted similarities in pluripotent and cancer stem cell gene
expression patterns [27] suggest that DNMT3B exon 10 may be
a specific biomarker of the stem cell component of some tumors.
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